VIDEO: Addition of abiraterone improves overall survival in two prostate cancer studies
Click Here to Manage Email Alerts
In this video, Ben Tran, MD, discusses the PEACE-1 and STAMPEDE studies that looked at the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy, which was found to improve survival vs. standard therapy.
"These two studies change standard of care for me," said Tran, a medical oncologist at Peter MacCallum Cancer Centre in Melbourne, Australia.
"In high-volume de novo metastatic prostate cancer, I will now lean towards a triplet of docetaxel, abiraterone and [androgen deprivation therapy (ADT)], and in patients [without metastatic disease] who meet the criteria, I would consider abiraterone for two years in conjunction with ADT," Tran said.
Collapse
Fizazi, K et al. Abstract LBA5_PR. Presented at ESMO Congress 2021 (virtual meeting); Sept. 16-21, 2021.
Attard G, et al. Abstract LBA4_PR. Presented at ESMO Congress 2021 (virtual meeting); Sept. 16-21, 2021.
Click Here to Manage Email Alerts